DK2914264T3 - 6-oxo-1,6-dihydro-pyridazinderivat til anvendelsen til behandlingen af hepatocellulært carcinom (hcc) - Google Patents
6-oxo-1,6-dihydro-pyridazinderivat til anvendelsen til behandlingen af hepatocellulært carcinom (hcc) Download PDFInfo
- Publication number
- DK2914264T3 DK2914264T3 DK13776720.8T DK13776720T DK2914264T3 DK 2914264 T3 DK2914264 T3 DK 2914264T3 DK 13776720 T DK13776720 T DK 13776720T DK 2914264 T3 DK2914264 T3 DK 2914264T3
- Authority
- DK
- Denmark
- Prior art keywords
- oxo
- dihydro
- methyl
- benzyl
- ylmethoxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
Claims (4)
1. 3-(l-{3-[5-(l-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo- 1.6- dihydro-pyridazin-3-yl)-benzonitril eller et farmaceutisk acceptabelt salt og/eller solvat deraf til anvendelsen til behandlingen af hepatocellulært carcinom (HCC).
2.
3-(l-{3-[5-(l-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo- 1.6- dihydro-pyridazin-3-yl)-benzonitril-hydrochlorid-hydrat til anvendelsen til behandlingen af hepatocellulært carcinom (HCC). 3. 3-(l-{3-[5-(l-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo- 1.6- dihydro-pyridazin-3-yl)-benzonitril ifølge krav 1 eller 2, hvor forbindelsen administreres til en patient i en mængde på 100 mg til 800 mg pr. dag.
4. 3-(l-{3-[5-(l-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo- 1.6- dihydro-pyridazin-3-yl)-benzonitril ifølge krav 1, 2 eller 3, hvor forbindelsen administreres oralt.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12007494 | 2012-11-02 | ||
| PCT/EP2013/002998 WO2014067610A1 (en) | 2012-11-02 | 2013-10-04 | A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2914264T3 true DK2914264T3 (da) | 2017-09-11 |
Family
ID=47143496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13776720.8T DK2914264T3 (da) | 2012-11-02 | 2013-10-04 | 6-oxo-1,6-dihydro-pyridazinderivat til anvendelsen til behandlingen af hepatocellulært carcinom (hcc) |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20150283137A1 (da) |
| EP (1) | EP2914264B1 (da) |
| JP (1) | JP6255028B2 (da) |
| KR (1) | KR102131588B1 (da) |
| CN (1) | CN104768553A (da) |
| AR (1) | AR093318A1 (da) |
| AU (1) | AU2013339823B2 (da) |
| BR (1) | BR112015008279A2 (da) |
| CA (1) | CA2890273C (da) |
| DK (1) | DK2914264T3 (da) |
| ES (1) | ES2646913T3 (da) |
| HK (1) | HK1211869A1 (da) |
| HR (1) | HRP20171295T1 (da) |
| HU (1) | HUE035483T2 (da) |
| IL (1) | IL238536B (da) |
| LT (1) | LT2914264T (da) |
| MX (1) | MX354518B (da) |
| NO (1) | NO2914264T3 (da) |
| PL (1) | PL2914264T3 (da) |
| PT (1) | PT2914264T (da) |
| RS (1) | RS56485B1 (da) |
| RU (1) | RU2650679C2 (da) |
| SG (1) | SG11201503214YA (da) |
| SI (1) | SI2914264T1 (da) |
| WO (1) | WO2014067610A1 (da) |
| ZA (1) | ZA201503924B (da) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105792641A (zh) | 2013-08-14 | 2016-07-20 | 有限会社日本通商 | 水栽培系统、和设置有水栽培系统的植物工厂以及由发泡聚苯乙烯泡沫制成的温室 |
| KR20220034183A (ko) * | 2019-07-10 | 2022-03-17 | 메르크 파텐트 게엠베하 | 약제학적 제제 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005057924A1 (de) * | 2005-12-05 | 2007-06-06 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102007032507A1 (de) * | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
| CA3014648C (en) * | 2009-01-08 | 2021-06-01 | Merck Patent Gmbh | Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof |
-
2013
- 2013-10-04 HU HUE13776720A patent/HUE035483T2/hu unknown
- 2013-10-04 DK DK13776720.8T patent/DK2914264T3/da active
- 2013-10-04 SG SG11201503214YA patent/SG11201503214YA/en unknown
- 2013-10-04 AU AU2013339823A patent/AU2013339823B2/en active Active
- 2013-10-04 LT LTEP13776720.8T patent/LT2914264T/lt unknown
- 2013-10-04 PL PL13776720T patent/PL2914264T3/pl unknown
- 2013-10-04 US US14/440,181 patent/US20150283137A1/en not_active Abandoned
- 2013-10-04 NO NO13776720A patent/NO2914264T3/no unknown
- 2013-10-04 BR BR112015008279A patent/BR112015008279A2/pt not_active Application Discontinuation
- 2013-10-04 SI SI201330832T patent/SI2914264T1/sl unknown
- 2013-10-04 EP EP13776720.8A patent/EP2914264B1/en active Active
- 2013-10-04 WO PCT/EP2013/002998 patent/WO2014067610A1/en active Application Filing
- 2013-10-04 JP JP2015541023A patent/JP6255028B2/ja active Active
- 2013-10-04 KR KR1020157014482A patent/KR102131588B1/ko active IP Right Grant
- 2013-10-04 CA CA2890273A patent/CA2890273C/en active Active
- 2013-10-04 ES ES13776720.8T patent/ES2646913T3/es active Active
- 2013-10-04 RS RS20171129A patent/RS56485B1/sr unknown
- 2013-10-04 CN CN201380057293.0A patent/CN104768553A/zh active Pending
- 2013-10-04 RU RU2015120692A patent/RU2650679C2/ru active
- 2013-10-04 MX MX2015005265A patent/MX354518B/es active IP Right Grant
- 2013-10-04 PT PT137767208T patent/PT2914264T/pt unknown
- 2013-11-01 AR ARP130103990A patent/AR093318A1/es not_active Application Discontinuation
-
2015
- 2015-04-30 IL IL238536A patent/IL238536B/en active IP Right Grant
- 2015-06-01 ZA ZA2015/03924A patent/ZA201503924B/en unknown
-
2016
- 2016-01-04 HK HK16100004.6A patent/HK1211869A1/xx unknown
-
2017
- 2017-08-28 HR HRP20171295TT patent/HRP20171295T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2646913T3 (es) | 2017-12-18 |
| EP2914264A1 (en) | 2015-09-09 |
| PT2914264T (pt) | 2017-11-14 |
| WO2014067610A1 (en) | 2014-05-08 |
| BR112015008279A2 (pt) | 2017-07-04 |
| AU2013339823A1 (en) | 2015-06-18 |
| RU2015120692A (ru) | 2016-12-27 |
| HK1211869A1 (en) | 2016-06-03 |
| NO2914264T3 (da) | 2018-01-06 |
| AR093318A1 (es) | 2015-05-27 |
| JP2015536957A (ja) | 2015-12-24 |
| KR102131588B1 (ko) | 2020-07-08 |
| HRP20171295T1 (hr) | 2017-10-20 |
| HUE035483T2 (hu) | 2018-05-02 |
| JP6255028B2 (ja) | 2017-12-27 |
| CN104768553A (zh) | 2015-07-08 |
| MX2015005265A (es) | 2015-07-17 |
| IL238536B (en) | 2019-01-31 |
| AU2013339823B2 (en) | 2018-01-04 |
| MX354518B (es) | 2018-03-08 |
| IL238536A0 (en) | 2015-06-30 |
| KR20150079942A (ko) | 2015-07-08 |
| SI2914264T1 (sl) | 2017-12-29 |
| LT2914264T (lt) | 2017-11-10 |
| ZA201503924B (en) | 2020-11-25 |
| PL2914264T3 (pl) | 2017-12-29 |
| US20150283137A1 (en) | 2015-10-08 |
| RU2650679C2 (ru) | 2018-04-17 |
| EP2914264B1 (en) | 2017-08-09 |
| RS56485B1 (sr) | 2018-01-31 |
| CA2890273A1 (en) | 2014-05-08 |
| CA2890273C (en) | 2021-10-26 |
| SG11201503214YA (en) | 2015-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2013234767B2 (en) | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with other anti-tumor compounds | |
| US20190388423A1 (en) | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an EGFR inhibitor | |
| US10231972B2 (en) | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative | |
| DK2914264T3 (da) | 6-oxo-1,6-dihydro-pyridazinderivat til anvendelsen til behandlingen af hepatocellulært carcinom (hcc) | |
| AU2013329865B2 (en) | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a MEK inhibitor | |
| CA2935892C (en) | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with gefitinib |